P107 Effectiveness of omalizumab on asthma control and lung function in severe allergic asthma patients in the Czech Republic

Background: Asthma is the most common chronic disease affecting children and altering their quality of life. The severity of asthma is often modulated by immunoglobulin E (IgE)-mediated allergen sensitization and is associated with comorbid allergic dis-eases. Omalizumab is a humanized monoclonal antibody anti-IgE, the first biological therapy approved to treat patients aged ≥6 years with severe allergic asthma. The primary objective of our study was to investigate the efficacy and safety of Omali-zumab in Romanian paediatric patients with severe allergic asthma. Methods: In this observational real-life study, 12 children aged 6 to 18 years, (mean age 12.4 years ) with severe allergic asthma received Omalizumab as an add-on treatment. The levels of asthma control, exacerbations, lung function and adverse events were evaluated at baseline and after the first year of treatment. Results: We noticed general improvements in total asthma symptom scores and the rate of exacerbation of severe asthma. Omalizumab increased the initial variables of lung function, and no serious adverse reactions were reported. FEV1 improved statistically significant after one year of treatment with Omalizumab, [ΔFEV1 (% pred.) =18.3, and similarly, ΔMEF50 (%) = 25.8]. The mean severe exacerbation rates due to asthma decreased from 4.1 (2.8 SD) to 1.15 (0.78 SD) during the treatment year (p<0.0001) with Omalizumab. Conclusions: Treatment with Omalizumab can be an effective and safe therapeutic option for Romanian children with severe allergic asthma, providing clinically relevant in-formation on asthma control and exacerbation rate in children and adolescents. The results highlighted the effect of Omalizumab in young patients, starting from the first year of treatment.

Download Full-text

Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma—A Romanian Perspective

Children ◽

10.3390/children8121141 ◽

2021 ◽

Vol 8 (12) ◽

pp. 1141

Author(s):

Elena Camelia Berghea ◽

Mihaela Balgradean ◽

Carmen Pavelescu ◽

Catalin Gabriel Cirstoveanu ◽

Claudia Lucia Toma ◽

...

Keyword(s):

Lung Function ◽

Children And Adolescents ◽

Allergic Asthma ◽

Asthma Control ◽

Immunoglobulin E ◽

Real Life ◽

First Year ◽

Severe Exacerbation ◽

Exacerbation Rate ◽

Severe Allergic Asthma

Background: Asthma is the most common chronic disease affecting children, with a negative impact on their quality of life. Asthma is often associated with comorbid allergic diseases, and its severity may be modulated by immunoglobulin E (IgE)-mediated allergen sensitization. Omalizumab is a humanized monoclonal anti-IgE antibody, the first biological therapy approved to treat patients aged ≥6 years with severe allergic asthma. The primary objective of our study was to investigate the efficacy and safety of Omalizumab in Romanian children with severe allergic asthma. Methods: In this observational real-life study, 12 children and adolescents aged 6 to 18 years (mean 12.4 years) with severe allergic asthma received Omalizumab as an add-on treatment. Asthma control, exacerbations, lung function, and adverse events were evaluated at baseline and after the first year of treatment. Results: We observed general improvement in total asthma symptom scores and reduction in the rate of exacerbation of severe asthma. Omalizumab treatment was associated with improvement in the measures of lung function, and no serious adverse reactions were reported. FEV1 improved significantly after one year of treatment with Omalizumab [ΔFEV1 (% pred.) = 18.3], and [similarly, ΔMEF50 (%) = 25.8]. The mean severe exacerbation rate of asthma decreased from 4.1 ± 2.8 to 1.15 ± 0.78 (p < 0.0001) during the year of treatment with Omalizumab. Conclusions: This study showed that Omalizumab can be an effective and safe therapeutic option for Romanian children and adolescents with severe allergic asthma, providing clinically relevant information on asthma control and exacerbation rate in children and adolescents. The results demonstrated the positive effect of Omalizumab in young patients with asthma, starting from the first year of treatment.

Download Full-text

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

Advances in Dermatology and Allergology ◽

10.5114/ada.2018.76606 ◽

2019 ◽

Vol 36 (1) ◽

pp. 34-43 ◽

Cited By ~ 1

Author(s):

Olga Růžičková Kirchnerová ◽

Tomáš Valena ◽

Jakub Novosad ◽

Milan Teřl

Keyword(s):

Czech Republic ◽

Allergic Asthma ◽

Real World ◽

The Czech Republic ◽

Severe Allergic Asthma

Download Full-text

Predictors of a Minimal Clinically Important Difference Following Omalizumab Treatment in Adult Patients With Severe Allergic Asthma

Frontiers in Medicine ◽

10.3389/fmed.2021.762318 ◽

2022 ◽

Vol 8 ◽

Author(s):

Wei-Chang Huang ◽

Pin-Kuei Fu ◽

Ming-Cheng Chan ◽

Chun-Shih Chin ◽

Wen-Nan Huang ◽

...

Keyword(s):

Lung Function ◽

Allergic Asthma ◽

Asthma Control ◽

Minimal Clinically Important Difference ◽

Adult Patients ◽

Blood Eosinophil ◽

Asthma Control Test ◽

Cross Sectional ◽

Clinically Important Difference ◽

Severe Allergic Asthma

Several factors have been found to be predictors of a good response following omalizumab treatment in patients with severe allergic asthma (SAA). However, it remains unclear whether clinical characteristics can predict a minimal clinically important difference (MCID) following omalizumab treatment in this population. Therefore, the aim of this study was to investigate the features associated with an MCID following omalizumab treatment in adult patients with SAA. Of the 124 participants enrolled in this retrospective, cross-sectional study, 94, 103, 20 and 53 achieved the MCID following treatment with omalizumab and were considered to be responders of exacerbation reduction (no exacerbation during the 1-year follow-up period or ≧50% reduction in exacerbations from baseline), oral corticosteroid (OCS) sparing (no use of OCS to control asthma during the study period or a reduction of the monthly OCS maintenance dose to <50% of baseline), lung function (an increase of ≧230 ml in the forced expiratory volume in 1 s from baseline) and asthma control (an increase of ≧3 points in the asthma control test score from baseline), respectively. Normal weight [<25 vs. ≧30 kg/m2, odds ratio (OR) = 3.86, p = 0.024] was predictive of a responder of reduction in exacerbations following omalizumab treatment while subjects with a blood eosinophil level of <300 cells/μL (<300 vs. ≧300 cells/μL, OR = 5.81, p = 0.001) were more likely to exhibit an MCID in OCS sparing. No factor was found to be a predictor of lung function or asthma control. When choosing treatment for adult patients with SAA, our findings may help to select those who may benefit the most from omalizumab treatment.

Download Full-text

Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients

10.1183/13993003.congress-2015.pa1091 ◽

2015 ◽

Author(s):

Yavuz Havlucu ◽

Arzu Yorgancioglu ◽

Fikret Kurhan ◽

Tugba Goktalay ◽

Aysin Sakar Coskun ◽

...

Keyword(s):

Allergic Asthma ◽

Asthma Control ◽

Severe Allergic Asthma ◽

Asthma Patients

Download Full-text

Classification of non-acute bronchial asthma according to allergy and eosinophil characteristics: a retrospective study

Allergy Asthma & Clinical Immunology ◽

10.1186/s13223-021-00546-1 ◽

2021 ◽

Vol 17 (1) ◽

Author(s):

Yi Jiang ◽

Ruoli An ◽

Li Cheng ◽

Qianru Yue ◽

Hanwei Zhang ◽

...

Keyword(s):

Retrospective Study ◽

Lung Function ◽

Allergic Asthma ◽

Asthma Management ◽

Effective Management ◽

Sputum Cytology ◽

Eosinophilic Asthma ◽

Asthma Patients ◽

Medical University

Abstract Background Investigating the endotypes of the different asthma phenotypes would help disease monitoring, prognosis determination, and improving asthma management standardization. This study aimed to classify asthma into four endotypes according to the allergic and eosinophilic characteristics and explore the phenotypes (clinical characteristics, pulmonary functions, and fractional expired nitric oxide (FeNO)) of each endotype. Methods This retrospective study included non-acute asthma patients treated at the First Hospital of Shanxi Medical University (05/2016–01/2018). The patients were classified into the eosinophilic allergic, eosinophilic non-allergic, non-eosinophilic allergic, and non-eosinophilic non-allergic asthma endotypes. Serum sIgE, lung function, FeNO, and induced sputum cytology were tested and compared among groups. Results Of the 171 included patients, 22 had eosinophilic allergic asthma, 17 had eosinophilic non-allergic asthma, 66 had non-eosinophilic allergic asthma, and 66 had non-eosinophilic non-allergic asthma. Lung function measurements (FEV1%, FEF25%, FEF50%, FEF75%, and FEF25–75%) showed that airway dysfunction was worse in eosinophilic non-allergic asthma than in the other three endotypes (all P < 0.001). In allergic asthma patients, eosinophilic asthma had worse airway dysfunction than non-eosinophilic asthma (all P < 0.05). Similar results were found in non-allergic asthma (all P < 0.01). The FeNO levels in eosinophilic allergic asthma were higher than in eosinophilic non-allergic and non-eosinophilic non-allergic asthma (both P = 0.001). Conclusions FeNO can objectively reflect eosinophilic airway inflammation in asthma. Endotypic classification of asthma patients regarding the allergic and eosinophilic characteristics is conducive to the effective management of patients with asthma.

Download Full-text